Protalix BioTherapeutics (PLX) Misses Q1 EPS by 8c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.67 --0%
Revenue Growth %: -15.8%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -15.8%
Financial Fact:
NET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of ($0.05), $0.08 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $10.11 million versus the consensus estimate of $21.6 million.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bending Spoons to acquire Miro at $1.36B enterprise value
- Commerce.com unveils cost-cutting plan targeting 20% margins by 2027
- Piper Sandler lists 5 chip stocks to buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
